Legend Biotech (LEGN) Presents Two-Year Analysis of CARTITUDE-1 Showing Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Mye

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. HUBS
3. SPY
4. NUE
5. AAPL
6. AZN
7. TRMD
8. RARE
9. RTB
10. INTU

Go back to Legend Biotech (LEGN) Presents Two-Year Analysis of CARTITUDE-1 Showing Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Mye
(NASDAQ: LEGN) Delayed: 17.75 +0.17 (0.97%)
Previous Close $17.58    52 Week High $ 
Open $17.71    52 Week Low $ 
Day High $17.86    P/E N/A 
Day Low $17.69    EPS $ 
Volume 36,593